Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
busulfan + cyclophosphamide + antithymocyte globulin + granulocyte-colony stimulating factor
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
A combination conditioning regimen used prior to hematopoietic stem cell transplantation. It consists of busulfan (an alkylating agent), cyclophosphamide (an immunosuppressive agent), antithymocyte globulin (for T-cell depletion), and granulocyte-colony stimulating factor (for stem cell mobilization). This regimen is designed to suppress the recipient's immune system, eliminate diseased cells, and create space for donor cells to engraft.
- Other names
- Bu/Cy/ATG/G-CSFATG-BuCy with G-CSF
02
Targets
DNACSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on busulfan + cyclophosphamide + antithymocyte globulin + granulocyte-colony stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on busulfan + cyclophosphamide + antithymocyte globulin + granulocyte-colony stimulating factor.